Curated News
By: NewsRamp Editorial Staff
October 22, 2024
ABVC BioPharma Receives $50,000 in Licensing Fees from AiBtl BioPharma Inc.
Discuss on Reddit
LinkedIn
Substack
TelegramTLDR
- ABVC BioPharma received $50,000 in licensing fees from AiBtl BioPharma, demonstrating confidence in their therapeutic programs.
- ABVC's psychiatric disorder pipeline, including MDD and ADHD treatments, received $50,000 in licensing fees from AiBtl BioPharma.
- ABVC's innovative treatments for psychiatric disorders are gaining momentum, supported by funding from AiBtl BioPharma, potentially improving the lives of patients.
- The global MDD and ADHD treatment markets are projected to grow steadily, offering a promising outlook for ABVC's therapeutic pipeline.
Impact - Why it Matters
This news matters because it highlights the financial backing and confidence in ABVC's therapeutic programs. The company's position in the growing MDD and ADHD markets is reinforced, with the potential for significant returns and value creation for investors.
Summary
ABVC BioPharma, Inc. has received an additional $50,000 in licensing fees from AiBtl BioPharma Inc., totaling $346,000 in licensing fees. The company has received 23M AiBtl shares and will obtain royalties of up to $100M after the product launches. The payment is tied to ABVC's psychiatric disorder pipeline, including treatments for MDD and ADHD. The global MDD and ADHD markets are projected to see significant growth, and ABVC is strategically positioned in these expanding markets.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, ABVC BioPharma Receives $50,000 in Licensing Fees from AiBtl BioPharma Inc.
